Please select the option that best describes you:
Do you routinely include sipuleucel-T as one of your lines of systemic therapy for metastatic castration resistant prostate cancer?
If so, how do you sequence this with other therapies? In addition, in the absence of an effect on radiographic PFS or serum PSA, how do you assess when to start the next therapy after vaccine administration?
Answer from: Medical Oncologist at Academic Institution
In select patients, I will use Sipuleucel-T as first line therapy for patient with early castrate resistant disease that are asymptomatic. Those that I use Sipuleucel-T I will observe them post therapy unless I see a rapid increase in PSA or other symptoms, then I will start AR directed therapy. Inc...
Sign in or Register to read more